4,4'-((1,3-phenylenebis(methylene))bis(oxy))dibenzimidamide | 118499-92-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4,4'-((1,3-phenylenebis(methylene))bis(oxy))dibenzimidamide
• 英文别名: 1,3-bis[(4-amidino)phenoxymethyl]benzene；4-[[3-[(4-Carbamimidoylphenoxy)methyl]phenyl]methoxy]benzamidine；4-[[3-[(4-carbamimidoylphenoxy)methyl]phenyl]methoxy]benzenecarboximidamide
• CAS: 118499-92-6
• 化学式: C₂₂H₂₂N₄O₂
• 分子量: 374.442
• InChiKey: OHCPXJHKRQZPCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  118
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1,3-bis{(4-cyano)-phenoxymethyl}benzene 在 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 以91%的产率得到4,4'-((1,3-phenylenebis(methylene))bis(oxy))dibenzimidamide
  参考文献：
  名称：

  使用双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的结构-活性研究

  摘要：

  喷他脒是一种 FDA 批准的抗寄生虫药，最近被鉴定为一种外膜破坏增效剂，可增强红霉素、利福平和新生霉素对革兰氏阴性菌的作用。同一项研究还描述了使用市售喷他脒类似物的初步构效关系。我们在这里报告了受喷他脒启发的更广泛的双脒组的设计、合成和评估。本研究既验证了先前观察到的喷他脒的协同活性，同时进一步评估了结构相似的双脒增强革兰氏阳性特异性抗生素对抗革兰氏阴性病原体的能力。在制备的双脒中，发现其中一些表现出比喷他脒更大的协同活性。鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠杆菌，包括耐多粘菌素和碳青霉烯的菌株。

  DOI：

  10.1021/acsinfecdis.1c00466

文献信息

• [EN] COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION OF ANTIBIOTICS<br/>[FR] COMPOSÉS POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES ET LA POTENTIALISATION D'ANTIBIOTIQUES
  申请人：UNIV GEORGIA STATE RES FOUND

  公开号：WO2021127452A1

  公开（公告）日：2021-06-24

  Compounds and methods for use to treat a bacterial infection caused by, for example, gram positive bacteria, gram negative bacteria, and/or mycobacteria are provided herein. Also provided herein are compounds and methods for use in potentiating the effect of an antibiotic in the treatment of a bacterial infection. Pharmaceutical compositions including the compounds as described herein are also provided.

  本文提供了用于治疗由革兰氏阳性细菌、革兰氏阴性细菌和/或分枝杆菌引起的细菌感染的化合物和方法。本文还提供了用于增强抗生素在治疗细菌感染中的效果的化合物和方法。还提供了包括本文所述化合物的药物组合物。
• Novel amidine compounds for treating microbial infections
  申请人：Tidwell R. Richards

  公开号：US20070088067A1

  公开（公告）日：2007-04-19

  Novel amidine and diamidine compounds are useful in the treatment of microbial infections, including mycobacterial, fungal and protozoal infections. Pharmaceutical formulations comprising these compounds can be used in methods of treating microbial infections.

  新型的胍类化合物，包括amidine和diamidine，对治疗微生物感染，包括结核菌、真菌和原虫感染具有有用的作用。含有这些化合物的药物制剂可用于治疗微生物感染的方法中。
• Amidine derivatives for treating amyloidosis
  申请人：Chalifour J. Robert

  公开号：US20070021483A1

  公开（公告）日：2007-01-25

  The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound. Among the compounds for use according to the invention are those according to the following Formula, such that, when administered, amyloid fibril formation, neurodegeneration, or cellular toxicity is reduced or inhibited:

  本发明涉及在治疗与淀粉样相关疾病中使用氨基脲类化合物。特别地，本发明涉及一种治疗或预防受试者淀粉样相关疾病的方法，包括向受试者施用治疗剂量的氨基脲类化合物。根据本发明使用的化合物包括以下化学式的化合物，当施用时，可减少或抑制淀粉样纤维形成、神经退行性或细胞毒性：
• Antitumor and Anti-Pneumocystis Carinii Activities of Novel Bisbenzamidines
  作者：Jean Jacques Vanden Eynde、Annie Mayence、Melissa T. Johnson、Tien L. Huang、Margaret S. Collins、Sandra Rebholz、Peter D. Walzer、Melanie T. Cushion、Isaac O. Donkor

  DOI：10.1007/s00044-005-0130-2

  日期：2005.4

  Among a library of 17 bisbenzamidines connected with various linkers, compounds with a flexible pentanediamide (10) or hexanediamide (12) linker were the most potent derivatives against rat Pneumocystis carinii (IC50 values of 3 and 2 nM, respectively) and had the highest selectivity index ratios (GI(50) of human tumor cells/IC50 of rat P. carinii cells) of > 10(4). Seven compounds caused 50% growth inhibition (GI(50)) of tumor cells at concentrations of < 100 mu M while the remaining ten were not cytotoxic. DNA binding affinity (Delta T-m) of the tested compounds did not correlate with either their anti-P. carinii activity or cytotoxicity.
• Novel bisbenzamidines as potential drug candidates for the treatment of Pneumocystis carinii pneumonia
  作者：Jean Jacques Vanden Eynde、Annie Mayence、Tien L Huang、Margaret S Collins、Sandra Rebholz、Peter D Walzer、Melanie T Cushion

  DOI：10.1016/j.bmcl.2004.06.034

  日期：2004.9

  A series of pentamidine congeners has been synthesized and screened for their in vitro activity against Pneumocystis carinii. Among the tested compounds, bisbenzamidines linked by a flexible pentanediamide or hexanediamide chain (7 and 9) emerged as exceptionally potent agents that were more effective and less toxic than pentamidine in the assays described in this study. (C) 2004 Elsevier Ltd. All rights reserved.